Work at Shionogi & Co. Ltd. has led to the discovery of fused-ring quinolone derivatives for the treatment of malaria.

Therapex Co. Ltd. has identified pyrimidine derivatives acting as EGFR (HER1; erbB1) mutant inhibitors described as potentially useful for the treatment of cancer.

Sumitomo Pharma Co. Ltd. has patented aminomethylcyclohexane derivatives acting as muscarinic M4 receptor antagonists. As such, they are described as potentially useful for the treatment of neurodegenerative diseases, cerebrovascular disorders, brain injury, movement and psychiatric disorders.

Frontier Medicines Corp. has divulged GTPase KRAS/PI3Kα interaction inhibitors. They are intended for use in the treatment of cancer.

Assembly Biosciences Inc. has synthesized tricyclic compounds potentially useful for the treatment of herpes simplex virus (HSV) infections.

Prospect Therapeutics Inc. has synthesized new substituted tricyclic derivatives acting as tyrosine-protein kinase JAK1 and non-receptor tyrosine-protein kinase TYK2 inhibitors.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has divulged new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an EGFR-targeting moiety via a linker.

Arcus Biosciences Inc. has reported piperidylurea compounds acting as Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists.

Pivot Therapeutics Inc. has patented RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors potentially useful for the treatment of cancer.

Triana Biomedicines Inc. has disclosed ALK tyrosine kinase receptor degradation inducers intended for use in the treatment of cancer.